Ultomiris Favored for Approval in EU for AChR-positive Generalized MG
Ultomiris (ravulizumab) has been recommended for approval in the European Union (EU) as an add-on therapy for most adults with generalized myasthenia gravis (gMG). The recommendation by the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, specifically covers gMG patients who are positive…